How a pharma company bought 2 accelerated approvals — never ran confirmatory trials — and cashed in until FDA said stop
The whole premise of the FDA’s accelerated approval pathway rests on the idea that clinical benefit will be established after the approval, via a confirmatory …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
